Navigation Links
New Roche Chlamydia Test Approved for Use in European Union

Test offers more reliable detection of Chlamydia trachomatis, the most

commonly reported sexually transmitted disease in Europe.

PLEASANTON, Calif., June 13 /PRNewswire/ -- Roche announced today that its new test for detection of Chlamydia trachomatis has received CE Mark certification, allowing it to be sold for clinical use in the European Union. It is designed with a dual target approach to help ensure reliability of test results even when mutations occur in the bacteria's cryptic plasmid DNA. According to Eurosurveillance, a leading independent scientific journal, Chlamydia trachomatis is the most commonly reported sexually transmitted disease in Europe. Although it often causes no symptoms, Chlamydia can, if left untreated, lead to complications such as pelvic inflammatory disease or infertility in women.

"Unexpected mutations in the DNA of an infectious agent such as Chlamydia can disrupt laboratory testing and, by extension, proper treatment of patients," said Teresa L. Wright, M.D., O.B.E., Chief Medical Officer at Roche Molecular Diagnostics. "Because it is impossible to predict when these mutations will occur, we have designed this test to detect all Chlamydia strains that may cause a deletion in the cryptic plasmid, including the variant originally detected in Sweden in 2006."

Chlamydia trachomatis is often referred to as a "silent" sexually transmitted disease because approximately three quarters of infected women have no symptoms. Once detected, Chlamydia trachomatis can easily be treated with antibiotics. If left untreated, health risks can include chronic pelvic pain, pelvic inflammatory disease, potentially fatal ectopic pregnancy, increased risk of HIV infection if exposed, and infertility.

The highly sensitive and reliable COBAS(R) TaqMan(R) CT Test v2.0 simultaneously detects two targets within the C. trachomatis cryptic plasmid and genome target DNA. In contrast to earlier generation tests, the COBAS(R) TaqMan(R) CT Test v2.0 offers real-time PCR testing on the automated COBAS(R) TaqMan(R) 48 Analyzer. This automated platform can produce up to 48 tests per run and provide results in only 2.5 hours after sample preparation. Amplification and detection in a closed system combined with Roche's proprietary AmpErase enzyme and internal controls for each test help prevent cross contamination. This enhances test results integrity and quality control in laboratories.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at

All trademarks used or mentioned in this release are protected by law.

For further information please contact:

Melinda Baker

Roche Molecular Diagnostics


Phone: 925-730-8379


Jessica Brillant

Roche Molecular Diagnostics


Phone : 925-730-8503


Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves New Roche West Nile Virus Blood Screening Test
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
6. MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
7. Nations Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract
8. Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments
9. Roche Extends Tender Offer for Ventana
10. Roche Offers Innovative Website Designed to Empower Cancer Patients
11. Neurochem reports results for third quarter of fiscal 2007
Post Your Comments:
(Date:11/25/2015)... ... ... Students and parents have something to be thankful for this Thanksgiving week ... California Casualty is proud to support the contest designed to utilize peer-to-peer ... the number one killer of young drivers. , Almost 1,000 entries of original ...
(Date:11/24/2015)... ... , ... New patients who wish to seek treatment for missing teeth can ... her Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 ... Missing teeth can lead to a variety of complications if they are not replaced ...
(Date:11/24/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced that Dr. Christine Milligan, Global Director, Strategic ... to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic of Korea, ...
(Date:11/24/2015)... Boston, MA (PRWEB) , ... November 24, 2015 ... ... today announced that the organization will waive paid entry and parking fees at ... in Hingham, and Monument Mountain in Great Barrington in support of REI’s Black ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... United States to support their local poison centers through donations on Tuesday, Dec. ... calls it “a day that inspires people to collaborate in improving their ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... , November 24, 2015 st  Scientific ... North America (RSNA) taking place in Chicago ... Booth 1122, Hall A. --> st  Scientific Assembly and ... (RSNA) taking place in Chicago ... Hall A. --> Molecular Dynamics will present its revolutionary ...
(Date:11/24/2015)... , November 24, 2015 The uptake of ... will be a key driver of market growth to 2021, ... recently approved and pipeline premium products for Type 1 Diabetes Mellitus (T1DM), ... says GBI Research . --> The uptake ... (T1DM), will be a key driver of market growth to 2021, ...
Breaking Medicine Technology: